Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$792K Hold
2,250
0.08% 37
2025
Q4
$736K Hold
2,250
0.06% 56
2025
Q3
$635K Hold
2,250
0.05% 63
2025
Q2
$628K Hold
2,250
0.06% 61
2025
Q1
$701K Hold
2,250
0.08% 50
2024
Q4
$586K Hold
2,250
0.08% 53
2024
Q3
$725K Hold
2,250
0.1% 55
2024
Q2
$703K Hold
2,250
0.11% 60
2024
Q1
$640K Hold
2,250
0.11% 61
2023
Q4
$648K Sell
2,250
-350
-13% -$95.4K 0.12% 68
2023
Q3
$699K Hold
2,600
0.15% 67
2023
Q2
$577K Hold
2,600
0.13% 77
2023
Q1
$629K Hold
2,600
0.18% 68
2022
Q4
$683K Hold
2,600
0.25% 63
2022
Q3
$586K Hold
2,600
0.39% 65
2022
Q2
$633K Hold
2,600
0.42% 63
2022
Q1
$629K Hold
2,600
0.37% 66
2021
Q4
$585K Hold
2,600
0.33% 71
2021
Q3
$553K Buy
+2,600
New +$598K 0.35% 69
2021
Q2
Sell
-2,600
Closed -$647K 82
2021
Q1
$647K Hold
2,600
0.36% 66
2020
Q4
$598K Buy
+2,600
New +$599K 0.37% 63

Other funds holding AMGN

Waycross Partners's AMGN Position: Q1 2026 in Review

Waycross Partners held its Amgen (AMGN) position steady in Q1 2026 at 2,250 shares worth $792K. The position accounts for 0.08% of the portfolio, ranked #37.

Waycross Partners first reported a position in AMGN in Q4 2020 and has held it in 21 quarters since. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Waycross Partners held 2,250 shares of Amgen worth $792K as of Q1 2026.
  • Waycross Partners left its Amgen share count unchanged in Q1 2026.
  • Amgen made up 0.08% of Waycross Partners's portfolio in Q1 2026, its #37 holding.
  • Waycross Partners first reported a position in Amgen in Q4 2020 and has held it in 21 quarters since.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Waycross Partners's 13F filing for Q1 2026, filed 7 May 2026.